Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
15.3.2021 14:33:36 CET | ViroGates | Company Announcement
COMPANY ANNOUNCEMENT - No. 6-2021 - 15 March 2021
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces that it has completed the development and regulatory approval (CE-IVD in Europe) of its suPARnostic® TurbiLatex product for the Abbott Alinity platform. ViroGates announced CE-IVD approval for the Abbott Architect line in June 2020. Today’s announcement means hospitals using the recent Abbott Alinity instrument platform can now run suPARnostic® TurbiLatex. Abbott Laboratories is a global medical technology company with a diagnostics division that has a turnover of more than 7 billion USD.
The Abbott Alinity platform is the most recent clinical chemistry and immunoassay system from Abbott. It was introduced in the European market in 2017 and has been rolled out gradually since then. It focuses on processing as many samples as possible with as small a “footprint” in the clinical lab as possible. Alinity is a fully automated system requiring no manual handling from the blood sampling until results are processed. The approval of suPARnostic® TurbiLatex for the Alinity platform complements the previous approvals for the Abbott Architect, the Roche Diagnostics cobas systems, and the Siemens ADVIA XPT system.
The suPARnostic® Turbilatex product is a pivotal element in ViroGates’ European expansion strategy with a particular focus on the acute care market
CEO Jakob Knudsen, says in a comment: ”We are excited to be able to offer suPARnostic® TurbiLatex on the Alinity platform from Abbott. While many Abbott Architect systems are in place in the market, the Alinity system will likely complement and replace the Architect systems over time. We are now well prepared to serve even more hospitals that are implementing this novel system from Abbott. We look forward to implementing suPARnostic® TurbiLatex at these hospitals to support faster and better patient triage decisions to the benefit of patients, hospitals, and payers.”
The announcement can be found at https://www.virogates.com/investor/announcements
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About the turbidimetric measurement principle
The suPARnostic® TurbiLatex product is based on a technology called turbidimetry that measures the loss of intensity of transmitted light in the blood sample being analysed. The principle of measuring blood samples by using turbidimetry is the basis of almost all central laboratory clinical chemistry platforms in hospitals.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect and Alinity instruments. ViroGates works with partners to develop solutions for other platforms.
Disclaimer
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com